BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8637720)

  • 1. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T; Perego R; Kruh GD
    Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.
    Buffa P; Manzella L; Consoli ML; Messina A; Vigneri P
    Proteins; 2007 Apr; 67(1):1-11. PubMed ID: 17211892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
    Brasher BB; Roumiantsev S; Van Etten RA
    Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity.
    Juang JL; Hoffmann FM
    Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk.
    Wang B; Mysliwiec T; Feller SM; Knudsen B; Hanafusa H; Kruh GD
    Oncogene; 1996 Oct; 13(7):1379-85. PubMed ID: 8875975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
    Van Etten RA; Debnath J; Zhou H; Casasnovas JM
    Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor.
    Yu HH; Zisch AH; Dodelet VC; Pasquale EB
    Oncogene; 2001 Jul; 20(30):3995-4006. PubMed ID: 11494128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An intramolecular SH3-domain interaction regulates c-Abl activity.
    Barilá D; Superti-Furga G
    Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homo- and hetero-oligomerization of the c-Abl kinase and Abelson-interactor-1.
    Fan PD; Cong F; Goff SP
    Cancer Res; 2003 Feb; 63(4):873-7. PubMed ID: 12591740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of ArgBP1, an Arg protein tyrosine kinase binding protein that is the human homologue of a CNS-specific Xenopus gene.
    Wang B; Mysliwiec T; Krainc D; Jensen RA; Sonoda G; Testa JR; Golemis EA; Kruh GD
    Oncogene; 1996 May; 12(9):1921-9. PubMed ID: 8649853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
    Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcellular localization of the Arg protein tyrosine kinase.
    Wang B; Kruh GD
    Oncogene; 1996 Jul; 13(1):193-7. PubMed ID: 8700546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
    Oda T; Kujovich J; Reis M; Newman B; Druker BJ
    Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
    Pisabarro MT; Serrano L; Wilmanns M
    J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-receptor tyrosine kinases c-Abl and Arg regulate the activity of C/EBPbeta.
    Li X; Liu X; Wang G; Zhu X; Qu X; Li X; Yang Y; Peng L; Li C; Li P; Huang W; Ma Q; Cao C
    J Mol Biol; 2009 Aug; 391(4):729-43. PubMed ID: 19563810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
    Jung JH; Pendergast AM; Zipfel PA; Traugh JA
    Biochemistry; 2008 Jan; 47(3):1094-104. PubMed ID: 18161990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.
    Mayer BJ; Baltimore D
    Mol Cell Biol; 1994 May; 14(5):2883-94. PubMed ID: 8164650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
    Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
    Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
    Reichman C; Singh K; Liu Y; Singh S; Li H; Fajardo JE; Fiser A; Birge RB
    Oncogene; 2005 Dec; 24(55):8187-99. PubMed ID: 16158059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.